Literature DB >> 8664138

Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study.

V Bataille1, J A Bishop, P Sasieni, A J Swerdlow, E Pinney, K Griffiths, J Cuzick.   

Abstract

The atypical mole syndrome (AMS) phenotype, characterised by a large number of common naevi as well as atypical naevi, has been described in families with a genetic susceptibility to melanoma. However, the importance of this phenotype for melanoma in the general population has not been conclusively determined. This study was designed to examine the types and distribution of naevi as well as the prevalence of the AMS phenotype in melanoma patients in England compared with controls. A total of 426 cutaneous melanoma cases (61% of all incident cases) aged 16-75 years were recruited between 1989 and 1993 from the north-east Thames region of the UK and 416 controls from the same age group were recruited over the same period and from the same region. Each subject answered a questionnaire covering demographic details, sun exposure history and other risk factors and underwent a skin examination with total body naevus count performed by a dermatologist. The AMS phenotype was defined using a scoring system. Atypical naevi gave the highest relative risk for cutaneous melanoma, with an odds ratio (OR) of 28.7 (P < 0.0001) for four or more atypical naevi compared with none. Many common naevi were also an important risk factor: the OR for 100 or more naevi 2 mm or above in diameter compared with 0-4 naevi was 7.7 (P < 0.0001). Melanoma was also associated with naevi on sun-exposed sites but also with naevi on non-sun-exposed sites such as the dorsum of the feet, buttocks and anterior scalp. Sixteen per cent of the cases had the AMS phenotype compared with 2% of the controls (OR 10.4, P < 0.0001). The AMS phenotype was more common in males than females (P = 0.008). The odds ratio for the presence of the AMS phenotype was dependent on age, with an odds ratio of 16.1 (95% CI 4.6-57.5) for the presence of the AMS phenotype if aged less than 40 compared with an odds ratio of 6.9 (95% CI 2.9-16.6) if aged 40 or more. The AMS phenotype was strongly predictive of an increased risk of melanoma outside the familial context.

Entities:  

Mesh:

Year:  1996        PMID: 8664138      PMCID: PMC2074531          DOI: 10.1038/bjc.1996.302

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  23 in total

1.  Variance estimators for attributable fraction estimates consistent in both large strata and sparse data.

Authors:  S Greenland
Journal:  Stat Med       Date:  1987-09       Impact factor: 2.373

2.  Benign melanocytic naevi as a risk factor for malignant melanoma.

Authors:  A J Swerdlow; J English; R M MacKie; C J O'Doherty; J A Hunter; J Clark; D J Hole
Journal:  Br Med J (Clin Res Ed)       Date:  1986-06-14

3.  High risk of malignant melanoma in melanoma-prone families with dysplastic nevi.

Authors:  M H Greene; W H Clark; M A Tucker; K H Kraemer; D E Elder; M C Fraser
Journal:  Ann Intern Med       Date:  1985-04       Impact factor: 25.391

4.  Demographic study of clinically atypical (dysplastic) nevi in patients with melanoma and comparison subjects.

Authors:  J J Nordlund; J Kirkwood; B M Forget; A Scheibner; D M Albert; E Lerner; G W Milton
Journal:  Cancer Res       Date:  1985-04       Impact factor: 12.701

5.  Number of melanocytic nevi as a major risk factor for malignant melanoma.

Authors:  E A Holly; J W Kelly; S N Shpall; S H Chiu
Journal:  J Am Acad Dermatol       Date:  1987-09       Impact factor: 11.527

6.  Risk factors for cutaneous malignant melanoma: the Western Canada Melanoma Study.

Authors:  R P Gallagher; J M Elwood; G B Hill
Journal:  Recent Results Cancer Res       Date:  1986

7.  Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'.

Authors:  W H Clark; R R Reimer; M Greene; A M Ainsworth; M J Mastrangelo
Journal:  Arch Dermatol       Date:  1978-05

8.  Dysplastic nevi on the scalp of prepubertal children from melanoma-prone families.

Authors:  M A Tucker; M H Greene; W H Clark; K H Kraemer; M C Fraser; D E Elder
Journal:  J Pediatr       Date:  1983-07       Impact factor: 4.406

9.  Ocular findings in patients with dysplastic nevus syndrome.

Authors:  R S Rodriguez-Sains
Journal:  Ophthalmology       Date:  1986-05       Impact factor: 12.079

10.  Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE).

Authors:  J M Bliss; D Ford; A J Swerdlow; B K Armstrong; M Cristofolini; J M Elwood; A Green; E A Holly; T Mack; R M MacKie
Journal:  Int J Cancer       Date:  1995-08-09       Impact factor: 7.396

View more
  41 in total

1.  Histopathological characteristics of small diameter melanocytic naevi.

Authors:  M Braun-Falco; R Hein; J Ring; N S McNutt
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

2.  Melanocytic nevi, nevus genes, and melanoma risk in a large case-control study in the United Kingdom.

Authors:  Julia A Newton-Bishop; Yu-Mei Chang; Mark M Iles; John C Taylor; Bert Bakker; May Chan; Susan Leake; Birute Karpavicius; Sue Haynes; Elaine Fitzgibbon; Faye Elliott; Peter A Kanetsky; Mark Harland; Jennifer H Barrett; D Timothy Bishop
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

Review 3.  Strategies for early melanoma detection: Approaches to the patient with nevi.

Authors:  Agnessa Gadeliya Goodson; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2009-05       Impact factor: 11.527

4.  Alcohol consumption and risk of melanoma among women: pooled analysis of eight case-control studies.

Authors:  Kyoko Miura; Michael S Zens; Tessa Peart; Elizabeth A Holly; Marianne Berwick; Richard P Gallagher; Thomas M Mack; J Mark Elwood; Margaret R Karagas; Adèle C Green
Journal:  Arch Dermatol Res       Date:  2015-07-16       Impact factor: 3.017

5.  Nevus count associations with pigmentary phenotype, histopathological melanoma characteristics and survival from melanoma.

Authors:  Nicholas J Taylor; Nancy E Thomas; Hoda Anton-Culver; Bruce K Armstrong; Colin B Begg; Klaus J Busam; Anne E Cust; Terence Dwyer; Lynn From; Richard P Gallagher; Stephen B Gruber; Diane E Nishri; Irene Orlow; Stefano Rosso; Alison J Venn; Roberto Zanetti; Marianne Berwick; Peter A Kanetsky
Journal:  Int J Cancer       Date:  2016-05-30       Impact factor: 7.396

6.  Does an increased number of moles correlate to a higher risk of melanoma?

Authors:  Mehul Bhatt; Adam Nabatian; David Kriegel; Hooman Khorasani
Journal:  Melanoma Manag       Date:  2016-05-19

7.  MelaNostrum: a consensus questionnaire of standardized epidemiologic and clinical variables for melanoma risk assessment by the melanostrum consortium.

Authors:  Alexander J Stratigos; Maria Concetta Fargnoli; Arcangela De Nicolo; Ketty Peris; Susana Puig; Efthymia Soura; Chiara Menin; Donato Calista; Paola Ghiorzo; Mario Mandala; Daniela Massi; Monica Rodolfo; Laura Del Regno; Irene Stefanaki; Helen Gogas; Veronique Bataille; Margaret A Tucker; David Whiteman; Eduardo Nagore; Maria Teresa Landi
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-09-14       Impact factor: 6.166

8.  Shorter telomere length in Europeans than in Africans due to polygenetic adaptation.

Authors:  Matthew E B Hansen; Steven C Hunt; Rivka C Stone; Kent Horvath; Utz Herbig; Alessia Ranciaro; Jibril Hirbo; William Beggs; Alexander P Reiner; James G Wilson; Masayuki Kimura; Immaculata De Vivo; Maxine M Chen; Jeremy D Kark; Daniel Levy; Thomas Nyambo; Sarah A Tishkoff; Abraham Aviv
Journal:  Hum Mol Genet       Date:  2016-03-02       Impact factor: 6.150

9.  Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi.

Authors:  Agnessa Gadeliya Goodson; Scott R Florell; Kenneth M Boucher; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2009-12-16       Impact factor: 11.527

10.  A variant in FTO shows association with melanoma risk not due to BMI.

Authors:  Mark M Iles; Matthew H Law; Simon N Stacey; Jiali Han; Shenying Fang; Ruth Pfeiffer; Mark Harland; Stuart Macgregor; John C Taylor; Katja K Aben; Lars A Akslen; Marie-Françoise Avril; Esther Azizi; Bert Bakker; Kristrun R Benediktsdottir; Wilma Bergman; Giovanna Bianchi Scarrà; Kevin M Brown; Donato Calista; Valérie Chaudru; Maria Concetta Fargnoli; Anne E Cust; Florence Demenais; Anne C de Waal; Tadeusz Dębniak; David E Elder; Eitan Friedman; Pilar Galan; Paola Ghiorzo; Elizabeth M Gillanders; Alisa M Goldstein; Nelleke A Gruis; Johan Hansson; Per Helsing; Marko Hočevar; Veronica Höiom; John L Hopper; Christian Ingvar; Marjolein Janssen; Mark A Jenkins; Peter A Kanetsky; Lambertus A Kiemeney; Julie Lang; G Mark Lathrop; Sancy Leachman; Jeffrey E Lee; Jan Lubiński; Rona M Mackie; Graham J Mann; Nicholas G Martin; Jose I Mayordomo; Anders Molven; Suzanne Mulder; Eduardo Nagore; Srdjan Novaković; Ichiro Okamoto; Jon H Olafsson; Håkan Olsson; Hubert Pehamberger; Ketty Peris; Maria Pilar Grasa; Dolores Planelles; Susana Puig; Joan Anton Puig-Butille; Juliette Randerson-Moor; Celia Requena; Licia Rivoltini; Monica Rodolfo; Mario Santinami; Bardur Sigurgeirsson; Helen Snowden; Fengju Song; Patrick Sulem; Kristin Thorisdottir; Rainer Tuominen; Patricia Van Belle; Nienke van der Stoep; Michelle M van Rossum; Qingyi Wei; Judith Wendt; Diana Zelenika; Mingfeng Zhang; Maria Teresa Landi; Gudmar Thorleifsson; D Timothy Bishop; Christopher I Amos; Nicholas K Hayward; Kari Stefansson; Julia A Newton Bishop; Jennifer H Barrett
Journal:  Nat Genet       Date:  2013-03-03       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.